Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Givinostat in Healthy Subjects (Part 3)
NCT05860114Phase 1Completed
- Sponsor
- Italfarmaco
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of givinostat in Duchenne muscular dystrophy (DMD), sponsored by Italfarmaco. Primary endpoints: Maximum Plasma Concentration at Day 1, Time to Maximum Plasma Concentration at Day 1 and 18 more. Started Mar 2022; status: completed.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05860114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860114.